Moxifloxacin-containing Regimen Greatly Reduces Time to Culture Conversion in Murine Tuberculosis

American Journal of Respiratory and Critical Care Medicine

Volumn 169, Issue 3, 2004, Pages 421-426

  Nuermberger, Eric L ^a   Yoshimatsu, Tetsuyuki ^a   Tyagi, Sandeep ^a   O'Brien, Richard J ^a   Vernon, Andrew N ^a   Chaisson, Richard E ^a   Bishai, William R ^a   Grosset, Jacques H ^a  

^a NONE

Author keywords

Fluoroquinolone; Mouse; Moxifloxacin; Treatment; Tuberculosis

Indexed keywords

ANTIINFECTIVE AGENT; HETEROCYCLIC COMPOUND; ISONIAZID; MOXIFLOXACIN; PYRAZINAMIDE; QUINOLINE DERIVATIVE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ANALYSIS OF VARIANCE; ANIMAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOAVAILABILITY; CELL CULTURE; CHEMOTHERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; CULTURE MEDIUM; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECT; DRUG EFFICACY; ERADICATION THERAPY; FEMALE; GROWTH, DEVELOPMENT AND AGING; LUNG INFECTION; MICROBIOLOGICAL EXAMINATION; MOUSE; MOUSE STRAIN; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROBABILITY; SENSITIVITY AND SPECIFICITY; TIME; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 1642537638     PISSN: 00030805     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.200310-1380oc     Document Type: Article

References (36)

1. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, Dye C. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003;163:1009-1021.
2. Dye C, Watt CJ, Bleed D. Low access to a highly effective therapy: a challenge for international tuberculosis control. Bull World Health Organ 2002;80:437-444.
3. Fox W. Whither short-course chemotherapy? Br J Dis Chest 1981;75:331-357.
4. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, Fujiwara P, Grzemska M, Hopewell PC, Iseman MD, et al. Treatment of tuberculosis. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America. Am J Respir Crit Care Med 2003;167:603-662.
5. World Health Organization. Treatment of tuberculosis: guidelines for national programmes. Publication no. WHO/CDS/TB/2003.313. Geneva, Switzerland: World Health Organization; 2003.
6. Lounis N, Bentoucha A, Truffot-Pcrnot C, Ji B, O'Brien RJ, Vernon A, Roscigno G, Grosset J. Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice. Antimicrob Agents Chemother 2001;45:3482-3486.
7. Grosset J, Ji B. Experimental chemotherapy of mycobacterial diseases. In: Gangadharam PRJ, Jenkins PA, editors. Mycobacteria, Vol. II: Chemotherapy. New York: Chapman & Hall; 1998. p. 51-97.
8. O'Brien RJ, Nunn PP. The need for new drugs against tuberculosis: obstacles, opportunities, and next steps. Am J Respir Crit Care Med 2001;163:1055-1058.
9. Global Alliance for Tuberculosis Drug Development. Tuberculosis: scientific blueprint for tuberculosis drug development. Tuberculosis (Edinb) 2001;81:1-52.
10. Ji B, Lounis N, Maslo C, Truffot-Pernot C, Bonnafous P, Grosset J. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998;42: 2066-2069.
11. Lubasch A, Keller I, Borner K, Kneppe P, Lode H. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrob Agents Chemother 2000;44:2600-2603.
12. Sullivan JT, Woodruff M, Lettieri J, Agarwal V, Krol GJ, Leese PT, Watson S, Heller AH. Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone. Antimicrob Agents Chemother 1999;43:2793-2797.
13. Stass H, Dalhoff A, Kubitza D, Schuhly U. Pharmacokinetics, safely, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Antimicrob Agents Chemother 1998;42:2060-2065.
14. Siefert HM, Domdey-Bette A, Henninger K, Hucke F, Kohlsdorfer C, Stass HH. Pharmacokineties of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species. J Antimicrob Chemother 1999;43(Suppl B):69-76.
15. Yoshimatsu T, Nuermberger E, Tyagi S, Chaisson R, Bishai W, Grosset J. Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis. Antimicrob Agents Chemother 2002;46: 1875-1879.
16. Miyazaki E, Miyazaki M, Chen JM, Chaisson RE, Bishai WR. Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis. Antimicrob Agents Chemother 1999;43:85-89.
17. Lenaerts AJ, Gruppo V, Brooks JV, Orme IM. Rapid in vivo screening of experimental drugs for tuberculosis using γ interferon gene-disrupted mice. Antimicrob Agents Chemother 2003;47:783-785.
18. Gosling RD, Uiso LO, Sam NE, Bongard E, Kanduma EG, Nyindo M, Morris RW, Gillespie SH. The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med 2003;168:1342-1345.
19. Pletz MW, Deroux A, Roth A, Mauch H, Lode H. Early bactericidal activity and efficacy of moxifloxacin versus isoniazid in the treatment of tuberculosis: a prospective, randomized study [abstract]. In: 41st Annual Meeting of the Infectious Diseases Society of America, San Diego, CA, October 9-12, 2003.
20. Hu Y, Coates AR, Mitchison DA. Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003;47:653-657.
21. Lalande V, Truffot-Pernot C, Paccaly-Moulin A, Grosset J, Ji B. Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice. Antimicrob Agents Chemother 1993;37:407-413.
22. Veziris N, Truffot-Pernot C, Aubry A, Jarlier V, Lounis N. Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo. Antimicrob Agents Chemother 2003;47:3117-3122.
23. Tuberculosis Research Centre C. Shortening short-course chemotherapy: a randomized clinical trial for treatment of smear positive pulmonary tuberculosis with regimens using olloxacin in the intensive phase. Indian J Tuberc 2002;49:27-38.
24. Nuermberger E, Yoshimatsu T, Tyagi S, Bishai WR, Grosset J. Assessment of moxifloxacin activity at clinically relevant dosages in the mouse model of tuberculosis [abstract ]. Am J Respir Crit Care Med 2003;169: A433.
25. Nuermberger E, Yoshimatsu T, Tyagi S, Bishai WR, Grosset J. Dramatic increase in the efficacy of combination therapy for tuberculosis (TB) with the use of moxilloxacin (M) in the murine model [abstract]. In: 43rd Annual Interscience Conference of Antimicrobial Agents and Chemotherapy, Chicago, IL, September 13-17, 2003.
26. Truffot-Pernot C, Ji B, Grosset J. Activities of pefloxacin and ofloxacin against mycobacteria: in vitro and mouse experiments. Tubercle 1991; 72:57-64.
27. Grosset J, Truffot-Pcrnot C, Lacroix C, Ji B. Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice. Antimicrob Agents Chemother 1992;36:548-551.
28. Dhillon J, Dickinson JM, Sole K, Mitchison DA. Preventive chemotherapy of tuberculosis in Cornell model mice with combinations of rifampin, isoniazid, and pyrazinamide. Antimicrob Agents Chemother 1996; 40:552-555.
29. Mitchison DA, Allen BW, Carrol L, Dickinson JM, Aber VR. A selective oleic acid albumin agar medium for tubercle bacilli. J Med Microbiol 1972;5:165-175.
30. Godfrey K. Statistics in practice: comparing the means of several groups. N Engl J Med 1985;313:1450-1456.
31. Wise R, Andrews JM, Marshall G, Hartman G. Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration. Antimicrob Agents Chemother 1999;43:1508-1510.
32. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-10.
33. Lecoeur HF, Truffot-Pernot C, Grosset JH. Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. Am Rev Respir Dis 1989;140:1189-1193.
34. Daniel N, Lounis N, Ji B, O'Brien RJ, Vernon A, Geiter LJ, Szpytma M, Truffot-Pernot C, Hejblum G, Grosset J. Antituberculosis activity of once-weekly rifapentine-containing regimens in mice. Long-term effectiveness with 6-and 8-month treatment regimens. Am J Respir Crit Care Med 2000;161:1572-1577.
35. Valerio G, Bracciale P, Manisco V, Quitadamo M, Legari G, Bellanova S. Long-term tolerance and effectiveness of moxifloxacin therapy for tuberculosis: preliminary results. J Chemother 2003;15:66-70.
36. Centers for Disease Control and Prevention (CDC): American Thoracic Society. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection - United States, 2003. MMWR Morb Mortal Wkly Rep 2003;52:735-739.